Login to Your Account

Cidara sayonara to topical VVC echinocandin

By Randy Osborne
Staff Writer

Tuesday, February 21, 2017

The endpoint miss in phase II with a topical version for moderate to severe acute vulvovaginal candidiasis (VVC, often known as yeast infection) did not dim Cidara Therapeutics Inc.'s optimism for an intravenous (I.V.) form of the echinocandin antifungal CD101 in candidemia, though Wall Street apparently felt otherwise.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription